Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
Phase 3
Completed
- Conditions
- Anemia in Chronic Kidney Disease in Non-dialysis Patients
- Interventions
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 616
- Registration Number
- NCT02021318
- Locations
- 🇦🇹
Site AT43009, Vienna, Austria
🇧🇾Site BY37503, Brest, Belarus
🇧🇾Site BY37501, Grodno, Belarus
A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels
Phase 1
Completed
- Conditions
- Phase 1BioavailabilityHealthy Subjects
- Interventions
- First Posted Date
- 2013-12-13
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 72
- Registration Number
- NCT02010944
- Locations
- 🇩🇪
Parexel, Berlin, Germany
A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)
Phase 3
Completed
- Conditions
- Neurogenic Detrusor OveractivityPediatric
- Interventions
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 23
- Registration Number
- NCT01981954
- Locations
- 🇺🇸
Site US1008 Pediatric Urology Associates, P.C., Tarrytown, New York, United States
🇧🇪Site BE3203 Gent University Hospital, Gent, Belgium
🇰🇷Site KR8207 Seoul National University Hospital, Seoul, Korea, Republic of
A Clinical Trial to Investigate Safety and Tolerability of ASP7962 in Healthy Humans
Phase 1
Completed
- Conditions
- SafetyPharmacokinetics of ASP7962Tolerability
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 48
- Registration Number
- NCT01981928
- Locations
- 🇬🇧
Parexel Early Phase Clinical Unit London, London, United Kingdom
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
Phase 3
Completed
- Conditions
- Urinary Bladder OveractiveUrinary Bladder Diseases\Urologic DiseasesOveractive BladderUrgency Incontinence
- Interventions
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 3527
- Registration Number
- NCT01972841
- Locations
- 🇺🇸
Site US10049 Coastal Clinical Research, Inc., Mobile, Alabama, United States
🇺🇸Site US10112 TFI, LLC, Mobile, Alabama, United States
🇺🇸Site US10104 Clinical Research Advantage, Inc., Chandler, Arizona, United States
A Study to Assess the Effect of Race on How a Single Dose of ASP3652 is Taken up, Metabolized and Distributed Through the Bodies of Young, Healthy Male and Female Subjects, and Its Safety and Tolerability
Phase 1
Completed
- Conditions
- PharmacodynamicsEffect of RacePharmacokineticsHealthy Subjects
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 64
- Registration Number
- NCT01958047
- Locations
- 🇬🇧
Parexel Early Phase Clinical Unit, Harrow, United Kingdom
A Study to Evaluate How Tamsulosin (at 1 Dose) and Solifenacin (at 2 Different Doses) Are Taken up From the Intestine, Distributed Through the Body and Eliminated From the Body When Administered in Combination as a Single Tablet (Called EC905)
Phase 1
Completed
- Conditions
- EC905PharmacokineticsMultiple DoseHealthy Subjects
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 27
- Registration Number
- NCT01953848
- Locations
- 🇬🇧
Parexel Early Phase Clinical Unit, Harrow, United Kingdom
A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin
Phase 1
Completed
- Conditions
- EC905PharmacokineticsHealthy Subjects
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 30
- Registration Number
- NCT01953887
- Locations
- 🇬🇧
Parexel, London, United Kingdom
A Study to Evaluate Whether Food Has an Effect on the Uptake of Solifenacin and Tamsulosin When Administered in a Combination Tablet
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 52
- Registration Number
- NCT01953861
- Locations
- 🇬🇧
Parexel Early Phase Clinical Unit, Harrow, United Kingdom
A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination Tablet
Phase 1
Completed
- Conditions
- Drug-Drug Interaction (DDI)Healthy Subjects
- Interventions
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2014-05-30
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 36
- Registration Number
- NCT01943487
- Locations
- 🇫🇷
SGS Aster, Paris, France